161 results on '"Van de Velde, Ann"'
Search Results
2. The Importance of Integrating the Visual Arts into the Medical Curriculum
3. Empowercare: Development and evaluation of a competency-framework and educational course to teach community-based professionals how to empower vulnerable community residents.
4. Combined Results of Two Cross-Sectional Surveys on the Participation in Clinical Trials and the e-Consent Procedure in the Landscape of Haematology
5. P-244 Teclistamab versus Belgian real-world clinical practice in triple-class exposed relapsed and refractory multiple myeloma patients using adjusted comparison
6. Disease Perception Is Correlated with Health-Related Quality of Life in Patients Suffering from Myelodysplastic Syndromes: Results of the Belgian Be-QUALMS Study
7. Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia
8. A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis
9. A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial
10. Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical Practice
11. Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes
12. Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical Practice.
13. Treatments in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Real-World Outcomes for Standard of Care (SOC)
14. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination
15. ERN-EuroBloodNet European Registry of Patients Affected by Red Blood Cell Disorders and COVID-19
16. Real-World Outcomes for Standard-of-Care Treatments in Patients with Relapsed/Refractory Multiple Myeloma
17. P-162: Compass: a prospective study comparing clinical evaluation with different geriatric screening methods in newly diagnosed elderly multiple myeloma patients
18. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial
19. Clinical and microbiological impact of discontinuation of fluoroquinolone prophylaxis in patients with prolonged profound neutropenia
20. Determining Factors Predictive of Cd34+ Cell Collection Efficiency in An Effort To Avoid Extended and Repeated Apheresis Sessions
21. COVID-19, impact on myeloma patients.
22. COVID-19, impact on myeloma patients
23. Stimulation of antiviral cellular immune responses by therapeutic vaccination of HIV-1-infected patients with dendritic cells transfected with gag, tat, rev and nef mRNA
24. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients
25. COVID-19, impact on myeloma patients
26. Cellulaire immuuntherapie bij kanker : nieuwe mogelijkheden met dendritische celvaccinaties
27. Classification and Characterization of Hereditary Types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (Unclassifiable) von Willebrand Disease
28. Characterization of Recessive Severe Type 1 and 3 von Willebrand Disease (VWD), Asymptomatic Heterozygous Carriers Versus Bloodgroup O-Related von Willebrand Factor Deficiency, and Dominant Type 1 VWD
29. Characterization, Classification, and Treatment of von Willebrand Diseases: A Critical Appraisal of the Literature and Personal Experiences
30. Response of von Willebrand Factor Parameters to Desmopressin in Patients with Type 1 and Type 2 Congenital von Willebrand Disease: Diagnostic and Therapeutic Implications
31. 7 - Treatments in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Real-World Outcomes for Standard of Care (SOC)
32. COMPARISON OF THE POWER OF PROCALCITONIN AND C-REACTIVE PROTEIN TO DISCRIMINATE BETWEEN DIFFERENT AETIOLOGIES OF FEVER IN PROLONGED PROFOUND NEUTROPENIA: A SINGLE-CENTRE PROSPECTIVE OBSERVATIONAL STUDY.
33. A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis.
34. A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis
35. Effectiveness of dendritic cells to prevent or delay relapse in acute myeloid leukemia
36. Adult acute precursor B-cell lymphoblastic leukemia presenting as hypercalcemia and osteolytic bone lesions
37. Plerixafor prescription modalities in autologous haematopoietic stem cell mobilization in Belgium.
38. Immunotherapy in leukaemia
39. Plerixafor in poor stem cell mobilizers : the belgian compassionate use program
40. Lenalidomide in relapsed refractory myeloma patients : impact of previous response to bortezomib and thalidomide on treatment efficacy: results of a medical need program in Belgium
41. Induction of Cytomegalovirus-Specific T Cell Responses in Healthy Volunteers and Allogeneic Stem Cell Recipients Using Vaccination With Messenger RNA–Transfected Dendritic Cells
42. Vaccination with WT1 mRNA-Electroporated Dendritic Cells: Report of Clinical Outcome in 66 Cancer Patients
43. Cost Analysis of Immunotherapy Using Dendritic Cells for Acute Myeloid Leukemia Patients
44. Adult acute precursor B-cell lymphoblastic leukemia presenting as hypercalcemia and osteolytic bone lesions.
45. Dendritic cell vaccination in malignant pleural mesothelioma: A phase I/II study.
46. Prevention Of Relapse In Acute Myeloid Leukemia By Dendritic Cell Vaccination: Report on a Phase II Study With 29 Patients
47. Lenalidomide in relapsed refractory myeloma patients: Impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium
48. WT1-targeted dendritic cell vaccination as a postremission treatment to prevent or delay relapse in acute myeloid leukemia.
49. Stimulation of antiviral cellular immune responses by therapeutic vaccination of HIV-1-infected patients with dendritic cells transfected with gag, tat, rev and nef mRNA
50. International Observational Study On Bortezomib (VELCADE) in Relapsed Multiple Myeloma: Preliminary Efficacy and Quality of Life (QoL) Results From the Belgian Population.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.